Hepatocyte transplantation for total liver repopulation.
Hepatocyte transplantation for total liver repopulation.
复制标题
DOI：
10.1007/s00534-005-0986-z
复制
发表时间：
2005-10
期刊：
影响因子：
--
通讯作者：
T. Mizuguchi;T. Mitaka;T. Katsuramaki;K. Hirata
中科院分区：
文献类型：
--
作者：
T. Mizuguchi;T. Mitaka;T. Katsuramaki;K. Hirata
肝细胞移植（HT）是一种有吸引力的替代肝移植的治疗方法。大量的实验已经证明了移植肝细胞替代全肝实质细胞的可行性。本文就HT促进肝脏再生的研究和临床报道作一综述。临床HT的细胞来源应是安全的。永生化细胞、肝干细胞和其他干细胞已被用于HT的实验模型。HT后细胞植入的确切机制尚未完全了解，尽管有一些标志物可用于检测和研究移植细胞。为了实现HT后的肝脏再生，轻度肝损伤可能需要促进细胞植入并用移植细胞替代宿主肝脏。激素因子也可用于同样的目的。尽管临床前研究的结果有望为细胞疗法带来临床益处，但HT的临床经验一直令人失望，除了少数病例。HT有可能成为未来肝移植的一种替代方法，但在建立有效的HT和肝脏替代治疗方法之前，还需要做许多努力。
Hepatocyte transplantation (HT) is an attractive therapeutic alternative to liver transplantation. A number of experiments have shown the feasibility of total liver parenchymal cell replacement by transplanted hepatocytes. In this review, we would like to highlight researches and clinical reports of HT for liver repopulation. Cellular source of clinical HT should be safety. Immortalized cells, hepatic stem cells, and other stem cells have been used for an experimental model for HT. The exact mechanism of the cell engraftment after HT has not been completely understood, although there were some markers to detect and investigate transplanted cells. In order to achieve liver repopulation following HT, a mild hepatic damage may need to facilitate cell engraftment and replace the host liver by transplanted cells. Hormonal factor may use for the same purpose. Despite the results of preclinical studies promising clinical benefits for cell therapy, the clinical experience of HT has been disappointing, except in a few cases. HT may become an alternative for liver transplantation in the future; however, many efforts should made before establishing an effective method for HT and liver replacement therapy.